Project Grant R01CA285743
Award Date
7/3/24
Completion Date
6/30/29
Dollars Obligated
$1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $703,410 to New York University School of Medicine to conduct research aimed at addressing the adaptive process of non-small cell lung cancer (NSCLC) transitioning to a squamous cell histology in response to targeted KRAS inhibitor therapy. The key objectives are to: 1) Identify specific chromatin regulators that drive the adeno-to-squamous transition, and target these vulnerabilities...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $267,527 to The University of Texas MD Anderson Cancer Center to conduct research aimed at overcoming resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors. The key objectives are to: Investigate the mechanism of resistance of SMARCA4 mutant lung cancer to KRAS G12C inhibitors like sotorasib. This will involve using genetic models and molecular characterizations to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a novel targeted approach for treating K-RAS(G12C) mutation-driven cancers. The $269,280 award, active from February 2025 to January 2027, supports research at Cold Spring Harbor Laboratory to investigate covalent labeling and targeted degradation of the K-RAS(G12C) oncogenic driver. The project involves synthesizing a library of hybrid ligands to evaluate their selectivity and...
The federal Project Grant award R01CA297605, totaling $696,569, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The funding supports research at New York University (NYU) School of Medicine aimed at targeting the small glycoprotein Lipocalin 2 (LCN2) as a novel therapeutic approach for treating KRAS-driven non-small cell lung cancer (NSCLC). The research seeks to characterize the impact of LCN2 on the tumor microenvironment,...
This Project Grant award of $356,850 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports a research effort led by The Medical College of Wisconsin, Inc. to characterize KRAS and other RAS gene mutations that may confer sensitivity to EGFR inhibitor drugs in colorectal cancer. The overarching goal is to identify additional RAS mutants that could benefit from EGFR-targeted therapies, which are currently limited due to the assumption that RAS mutations...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports a $352,275 research project to develop novel therapeutic approaches for treating lung cancer with co-occurring KRAS and LKB1 mutations. The research, conducted by the Regents of the University of Minnesota, aims to assess the safety and efficacy of a mitochondria-targeted metformin analog called "MitoMet" in suppressing the malignant...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $433,256 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding supports research to identify novel targets and develop lead compounds to overcome resistance to KRAS inhibitors for lung, colon, and other cancers. The project leverages fragment-based chemoproteomics approaches to probe biological target...
This $680,507 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to elucidate mechanisms of cancer persister cell drug tolerance and identify druggable targets to eliminate persister populations in KRAS-mutant non-small cell lung cancer. The 5-year project, awarded on April 1, 2025, will be conducted by the Regents of the University of California, San Francisco (UCSF), a leading academic medical center and research...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) in the amount of $730,407 will support research to investigate how inhibiting the ULK1 protein kinase impacts tumor and immune cell metabolism in lung cancer. The research aims to elucidate the interconnected effects of ULK1 inhibition on lung tumor cell metabolism and the tumor microenvironment, including immune cell function. Key activities include using stable isotope tracing and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $191,675.00 to The University of Texas Southwestern Medical Center to conduct research on the role of Jumonji lysine demethylases (Jumonji KDMs) in small cell lung cancer (SCLC). The goal is to develop new therapeutic strategies targeting Jumonji KDMs, either as first-line therapy, second-line therapy for SCLC resistant to standard chemotherapy, or in combination with other...